Does Tuberculosis Risk Differ Among TNF Inhibitors?


Reactivation of latent tuberculosis is a recognized risk of TNF inhibitor use.  While there has been circumstantial evidence of greater risk with the monoclonal antibody TNF inhibitors (e.g. infliximab and adalimumab) compared with decoy receptor TNF inhibitors (e.g. etanercept), there have been few direct comparisons.  Here, Dixon et al (Ann Rheum Dis 2010; 69: 522-528) […]

FDA Launches Safety Review of TNF Inhibitors in Children

The U.S. Food and Drug Administration released an early communication regarding a plan to investigate a possible association between TNF inhibitor therapy and cancer in children receiving these agents for treatment of juvenile idiopathic arthritis (JIA) and Crohn’s disease.